Dong Maryline, Pfeiffer Bernhard, Altmann Karl-Heinz
ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, HCI H 405, CH-8093 Zürich, Switzerland.
ETH Zürich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Vladimir-Prelog-Weg 4, HCI H 405, CH-8093 Zürich, Switzerland.
Drug Discov Today. 2017 Mar;22(3):585-591. doi: 10.1016/j.drudis.2016.11.015. Epub 2016 Nov 24.
Natural products (NPs) have been at the origin of several established drugs against tuberculosis (TB). Although the current clinical TB pipeline does not feature any candidates derived from new NP scaffolds, numerous novel NPs or NP analogs have been discovered in the recent past with promising activity against Mycobacterium tuberculosis (Mtb). This includes newly discovered structures as well as known NP classes that had not been previously recognized to be active against Mtb. These compounds could help to replenish the dry clinical TB pipeline and, thus, contribute to improvements in the treatment of a devastating disease.
天然产物一直是多种已获批的抗结核药物的来源。尽管目前的临床抗结核药物研发中没有来自新天然产物骨架的候选药物,但最近已发现了许多对结核分枝杆菌(Mtb)具有潜在活性的新型天然产物或天然产物类似物。这包括新发现的结构以及先前未被认为对Mtb有活性的已知天然产物类别。这些化合物有助于充实抗结核临床药物研发的空白,从而推动对这一致命疾病治疗方法的改进。